Hier die alternative:
BioLife designs and manufactures cGMP bio-preservation media products. Basically that means the company creates a type of serum that is ideal for transporting and storing cells, tissues or organs. This product caters to the regenerative medicine market (better known to the public as stem cells), by allowing much longer shelf life and preservation of drugs/treatments. BioLife has several patents surrounding this technology, and is working to gain more.
Currently, there are over 100 clinical trials that involve BioLife's products; they vary from pre-clinical to Phase III. In each of these drugs BioLife acts as a storage/shipment medium, and is permanently included the 'recipe' for that treatment. Thus, when a drug that uses BioLife's preservation media gets FDA approval and begins commercialization, it will be forced to use the media in every application. BioLife currently estimates that the approval and then commercialization of a single drug could add between $500,000-$2,000,000 in annual revenue.
Betting on BioLife is a numbers game, not an attempt at understanding a complex proprietary medicine. For the past 3 years BioLife has been filling up its pipeline with new drugs, and is closer than ever to one of its customers receiving FDA approval. Of the 100+ total, 10 are in Phase III trials and 47 are in Phase II as of January 9th, 2014 (according to this research report done by LifeSci Advisors). Generally a Phase III trial can be 5-10X larger than Phase II, which is already 2-3X larger than Phase I. For this reason, BioLife stands to get a major tailwind over the next several quarters as a big portion of its pipeline enters Phase III.
Recently BioLife completed a $13M+ capital raise and debt conversion, while simultaneously up listing from the OTC to the NASDAQ. These events a are a major positive for the company and gives BioLife enough capital to operate without dilution for ideally the next 3-4 quarters, at least. BioLife was almost operating at breakeven throughout 2013, and appears to be headed towards profitability over the course of 2014. The market hasn't reacted kindly to these events, and as a consequence has punished the stock, and it now trades near 52-week lows. The most likely reason for the fall was the amount of dilution that occurred during the debt conversion/offering, as well as the overall time it took to complete the process. During the process BioLife's outstanding share-count more than doubled from ~5M to 12M. Although at first glance this is a little concerning, it had to be done for the longevity of the company, and a dilutive event of this magnitude appears to be a one time occurrence.
BioLife has completely transformed its balance sheet thanks to this recent financial engineering. The company ended the year with less than $200K in cash, and more than $10M in debt. Now BioLife has $13M+ in cash, with $0 debt. This means at $3.64 BioLife essentially has a market capitalization of just $30M.
Even without a commercially approved drug BioLife is already generating close to $9M in revenue per year and closing in on profitability. The approval of just 1-2 of its clients would provide a major boost for BioLife's core product revenue, and reinforce the viability of the company's long-term model
MFG
Chali |
Thread abonnieren
